RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 8, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions

NMIBC

Interventions

DRUG

RC48-ADC in Combination with gemcitabine

RC48-ADC IV (intravenous) 2.0mg/kg IV, Q2W, 8W; Q4W, 40W Gemcitabine Intravesical 1000mg induction QW,8W; maintenance Q4W,40W

Trial Locations (1)

RECRUITING

Peking University First Hosptital, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY